Sign In
Buy GDRX
$2.57
-0.0900 (-3.38%)
At Close: Jun 22, 2026
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing
09:00am, Monday, 09'th Jun 2025
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of GoodRx Community Link. Designed to address the indu
GoodRx: Stabilizing Revenue Amid Healthy Profit Gains
03:59am, Friday, 06'th Jun 2025
I'm reiterating my Buy rating on GoodRx, as its valuation is compelling and the business is showing signs of stabilization under new leadership. GoodRx's recurring revenue base, expanding pharma partn
GoodRx to Launch Direct Contracting for Independent Community Pharmacies
09:00am, Thursday, 22'nd May 2025
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that it will launch a new offering for independent community phar
GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst
02:14pm, Monday, 19'th May 2025
JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings GDRX following the company's first-quarter earnings.
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
10:10am, Monday, 12'th May 2025
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
GDRX vs. PGNY: Which Stock Should Value Investors Buy Now?
12:40pm, Thursday, 08'th May 2025
Investors looking for stocks in the Medical Services sector might want to consider either GoodRx Holdings, Inc. (GDRX) or Progyny (PGNY). But which of these two stocks is more attractive to value inve
GoodRx Holdings, Inc. (GDRX) Q1 2025 Earnings Call Transcript
12:20pm, Thursday, 08'th May 2025
GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Aubrey Reynolds – Director-Investor Relations Wendy Barnes – President and Chief E
Is GoodRx (GDRX) a Great Value Stock Right Now?
10:40am, Thursday, 08'th May 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Compared to Estimates, GoodRx (GDRX) Q1 Earnings: A Look at Key Metrics
09:00pm, Wednesday, 07'th May 2025
Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates
07:51pm, Wednesday, 07'th May 2025
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago.
GoodRx Holdings, Inc. (GDRX) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Wednesday, 30'th Apr 2025
GoodRx (GDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call
04:05pm, Wednesday, 09'th Apr 2025
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced it will releas
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform
01:01pm, Tuesday, 08'th Apr 2025
GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
GoodRx Introduces New E-commerce Experience for Retail Pharmacies
09:00am, Thursday, 03'rd Apr 2025
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced a new e-commerce experience for retail pharmacies that improves h
GoodRx: Great Value For Patient Investors (Upgrade)
04:16pm, Monday, 24'th Mar 2025
GoodRx is a great small-cap value stock to buy amid the recent downturn. I'm upgrading the stock to a buy. GoodRx showcases strong adjusted EBITDA despite slower growth, making it an attractive target
